Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase IIb trial

B-cell activating factor may be involved in the failure of B-cell depleting therapy with rituximab in immune thrombocytopenia (ITP) by promoting the emergence of splenic long-lived plasma cells. From results obtained in mouse models, we hypothesized that combining rituximab with sequential injection...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahévas, Matthieu, Azzaoui, Imane, Crickx, Etienne, Canoui-Poitrine, Florence, Gobert, Delphine, Languille, Laetitia, Limal, Nicolas, Guillaud, Constance, Croisille, Laure, Jeljeli, Mohamed, Batteux, Fréderic, Baloul, Samia, Fain, Olivier, Pirenne, France, Weill, Jean-Claude, Reynaud, Claude-Agnès, Godeau, Bertrand, Michel, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409028/
https://www.ncbi.nlm.nih.gov/pubmed/32817288
http://dx.doi.org/10.3324/haematol.2020.259481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409028/
https://www.ncbi.nlm.nih.gov/pubmed/32817288
http://dx.doi.org/10.3324/haematol.2020.259481

Ejemplares similares